Seven hospital and pharmacist groups want HHS Secretary Alex Azar
to order drugmakers to comply with requirements outlined under the 340B drug
pricing program, after AstraZeneca, Eli Lilly, Merck, Novartis and Sanofi
indicated they might withhold 340B discounts. "If left unaddressed, these
actions will open the way for other drug manufacturers to deny discounts for
other products" and they will hurt millions of people who depend on 340B
program participants for care, the groups wrote in a letter to Azar.
No comments:
Post a Comment